4-[(3-chloro-2-methylphenyl)methyl]-5-ethyl-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one | 1256289-83-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[(3-chloro-2-methylphenyl)methyl]-5-ethyl-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one
• 英文别名: 4-[(3-chloro-2-methylphenyl)methyl]-5-ethyl-2-morpholin-4-yl-[1,3]thiazolo[4,5-d]pyrimidin-7-one
• CAS: 1256289-83-4
• 化学式: C₁₉H₂₁ClN₄O₂S
• 分子量: 404.92
• InChiKey: VJXHSFQZVFLQBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  86.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(3-chloro-2-methylphenyl)methyl]-5-ethyl-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one 在 溴 、 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 以92%的产率得到5-(1-bromoethyl)-4-[(3-chloro-2-methylphenyl)methyl]-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one
  参考文献：
  名称：

  [EN] THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
  [FR] DÉRIVÉS DE THIAZOLOPYRIMIDINONE COMME INHIBITEURS DE LA KINASE PI3

  摘要：

  这项发明涉及噻唑吡咯嘧啶酮衍生物在调节磷脂酰肌醇3' OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性或功能方面的用途，适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及噻唑吡咯嘧啶酮在治疗以下一种或多种疾病状态中的用途：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性噻唑吡咯嘧啶酮化合物用于治疗癌症。

  公开号：

  WO2010135504A1

文献信息

• THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：Lin Hong

  公开号：US20120053147A1

  公开（公告）日：2012-03-01

  This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3K}, PI3Kβ, and/or PI3Kγ.

  本发明涉及公式（I）的新化合物及其衍生物，可用于调节磷脂酰肌醇3′ OH激酶家族（以下简称PI3激酶）的活性或功能，特别是适用于PI3Kα，PI3K}，PI3Kβ和/或PI3Kγ的抑制。
• Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
  申请人：Lin Hong

  公开号：US08410095B2

  公开（公告）日：2013-04-02

  This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ.

  本发明涉及式（I）的新型化合物及其衍生物，用于调节，特别是抑制磷脂酰肌醇3'-OH激酶家族（以下简称PI3激酶），适用于PI3Kα，PI3Kδ，PI3Kβ和/或PI3Kγ的活性或功能。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF
  申请人：UPDATE PHARMA INC.

  公开号：US20160166546A1

  公开（公告）日：2016-06-16

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.